Drug Trial Radar · NCT05012423
FTIH Study of ECC0509 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Jul 26, 2021
Primary completion
Jul 22, 2023
Study completion Jul 22, 2023
Sponsor
- Lead sponsor
- EccogeneIndustry
- Sponsor type
- Industry
- First posted
- Aug 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.
Conditions
- Nonalcoholic Steatohepatitis
- Osteoarthritis
Interventions
PlaceboDrug
Matching Placebo will be administered as oral capsules.
ECC0509Drug
ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.
PlaceboDrug
Matching Placebo will be given orally during each dosing day.
ECC0509Drug
ECC0509 1 mg and 10 mg capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinationsTime frame: SAD: Up to Day 8. MAD: Up to Day 21.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.